HLA-DR expression, cytokines and bioactive lipids in sepsis

Archives of Medical Science

Volumn 10, Issue 2, 2014, Pages 325-335

  Das, Undurti ^a  

^a UND Life Sciences   (United States)

Author keywords

Bioactive lipids; Cold inducible RNA binding protein; Ghrelin; Lipoxins; Maresins; Nitrolipids; Nociceptin; Protectins; Resolvins; Sepsis

Indexed keywords

15 EPI 16 (PARA FLUOROPHENOXY) LIPOXIN A4 METHYL ESTER; 15 METHYL LIPOXIN A4; ANTIINFECTIVE AGENT; CD11B ANTIGEN; CD59 ANTIGEN; COLD INDUCIBLE RNA BINDING PROTEIN; CYTOKINE; GAMMA INTERFERON; GHRELIN; HIGH MOBILITY GROUP B1 PROTEIN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOTRIENE; LIPID; LIPID PEROXIDE; LIPOXIN; LIPOXIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NOCICEPTIN; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; RNA BINDING PROTEIN; THROMBOXANE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIINFLAMMATORY ACTIVITY; BACTERIAL CLEARANCE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LEUKOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MICROBIAL ACTIVITY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY INFECTION; REVIEW; SECONDARY INFECTION; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE;

EID: 84901040256     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2014.42586     Document Type: Review

References (63)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10. (Pubitemid 32641789)
2. Das UN. Critical advances in septicemia and septic shock. Crit Care 2000; 4: 290-4.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50. (Pubitemid 36056721)
4. Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 2004; 122: 765-71. (Pubitemid 39434758)
5. Monneret G. How to identify systemic sepsis-induced immunoparalysis. Adv Sepsis 2005; 4: 42-9.
6. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91. (Pubitemid 30394990)
7. Schwartz DA. The role of TLR4 in endotoxin responsiveness in humans. J Endotoxin Res 2001; 7: 389-93. (Pubitemid 34048541)
8. Shishido T, Nozaki N, Takahashi H, et al. Central role of endogenous Toll-like receptor-2 activation in regulating inflammation, reactive oxygen species production, and subsequent neointimal formation after vascular injury. Biochem Biophys Res Commun 2006; 345: 1446-53. (Pubitemid 43817893)
9. Norris PC, Reichart D, Dumlao DS, Glass CK, Dennis EA. Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype. J Leukoc Biol 2011; 90: 563-74.
10. Lefebvre JS, Marleau S, Milot V, et al. Toll-like receptor ligands induce polymorphonuclear leukocyte migration: key roles for leukotriene B4 and platelet-activating factor. FASEB J 2010; 24: 637-47.
11. Balistreri CR, Caruso C, Listì F, Colonna-Romano G, Lio D, Candore G. LPS-mediated production of pro/anti-inflammatory cytokines and eicosanoids in whole blood samples: biological effects of +896A/G TLR4 polymorphism in a Sicilian population of healthy subjects. Mech Ageing Dev 2011; 132: 86-92.
12. Font-Nieves M, Sans-Fons MG, Gorina R, et al. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J Biol Chem 2012; 287: 6454-68.
13. Gorina R, Font-Nieves M, Márquez-Kisinousky L, Santalucia T, Planas AM. Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFκB signaling, MAPK, and Jak1/Stat1 pathways. Glia 2011; 59: 242-55.
14. Lu J, Jilling T, Li D, Caplan MS. Polyunsaturated fatty acid supplementation alters proinflammatory gene expression and reduces the incidence of necrotizing enterocolitis in a neonatal rat model. Pediatr Res 2007; 61: 427-32. (Pubitemid 46569295)
15. Caplan MS, Russell T, Xiao Y, Amer M, Kaup S, Jilling T. Effect of polyunsaturated fatty acid (PUFA) supplementation on intestinal inflammation and necrotizing enterocolitis (NEC) in a neonatal rat model. Pediatr Res 2001; 49: 647-52. (Pubitemid 32390853)
16. Duffield JS, Hong S, Vaidya VS, et al. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006; 177: 5902-11. (Pubitemid 44628803)
17. Hassan IR, Gronert K. Acute changes in dietary omega-3 and omega-6 polyunsaturated fatty acids have a pronounced impact on survival following ischemic renal injury and formation of renoprotective docosahexaenoic acid-derived protectin D1. J Immunol 2009; 182: 3223-32.
18. Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009; 461: 1287-92.
19. Bitto A, Minutoli L, David A, et al. Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis. Crit Care 2012; 16: R32.
20. Toufekoula C, Papadakis V, Tsaganos T, et al. Compartmentalization of lipid peroxidation in sepsis by multi-drug- resistant gram-negative bacteria: experimental and clinical evidence. Crit Care 2013; 17: R6.
21. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4. (Pubitemid 17181429)
22. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4. (Pubitemid 18005583)
23. Hatherill M, Tibby SM, Turner C, et al. Procalcitonin and cytokine levels: relationship to organ failure and mortality in pediatric septic shock. Crit Care Med 2000; 28: 2591-4. (Pubitemid 30604475)
24. Moore TA, Lau HY, Cogen AL, et al. Anti-tumor necrosis factor-alpha therapy during murine Klebsiella pneumoniae bacteremia. Shock 2003; 20: 309-15.
25. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high mobility group box-1. Proc Natl Acad Sci USA 2004; 101: 296-301. (Pubitemid 38084244)
26. Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001; 164: 1768-73. (Pubitemid 33152308)
27. Das UN. Can Sepsis and other critical illnesses be predicted and prognosticated? Adv Sepsis 2006; 5: 52-9.
28. Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011; 306: 2594-605.
29. Simon PM, Delude RL, Lee M, et al.; GenIMS Investigators. Duration and magnitude of hypotension and monocyte deactivation in patients with community-acquired pneumonia. Shock 2011; 36: 553-9.
30. Babior BM, Curnutte JT, Kipnes RS. Biological defense mechanisms. Evidence for the participation of superoxide in bacterial killing by xanthine oxidase. J Lab Clin Med 1975; 85: 235-44.
31. Fang FC. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004; 2: 820-32. (Pubitemid 39317463)
32. Qian SY, Wang HP, Schafer FQ, Buettner GR. EPR detection of lipid-derived free radicals from PUFA, LDL, and cell oxidations. Free Radic Biol Med 2000; 29: 568-79.
33. Brunialti MKC Martos LSW, Machado FR, Assunacao MS, Blecher S, Salomao R. Expression of cell surface receptors and oxidative metabolism modulation in the clinical continuum of sepsis. Crit Care 2008; 12: R25.
34. Guillou PJ. Biological variation in the development of sepsis after surgery or trauma. Lancet 1993; 342: 217-20. (Pubitemid 23214641)
35. Hershman MJ, Cheadle WG, Wellhausen SR, Davidson PF, Polk SC. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990; 77: 204-7. (Pubitemid 20055846)
36. Carey PD, Wakefield CH, Thayeb A, Monson JRT, Guillou PJ. Preservation of neutrophil antimicrobial function after laparoscopic surgery. Br J Surg 1992; 79: 1223.
37. Das UN. Insulin and the critically ill. Crit Care 2002; 6: 262-3.
38. Wu JF, Ma J, Chen J, et al. Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis. Crit Care 2011; 15: R220.
39. Cheron A, Floccard B, Allaouchiche B, et al. Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care 2010; 14: R208.
40. Lukaszewicz AC, Grienay M, Resche-Rigon M, et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med 2009; 37: 2746-52.
41. Monneret G, Lepape A, Voirin N, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 2006; 32: 1175-83. (Pubitemid 44232412)
42. Venet F, Tissot S, Debard AL, et al. Decreased monocyte human leukocyte antigen-DR expression after severe burn injury: correlation with severity and secondary septic shock. Crit Care Med 2007; 35: 1910-7. (Pubitemid 47220366)
43. Gouel-Chéron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G; AzuRea Group. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS One 2012; 7: e33095.
44. Landelle C, Lepape A, Voirin N, et al. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med 2010; 36: 1859-66.
45. Wu J, Liu Z, Zhang Y, et al. Age-dependent alterations of HLA-DR expression and effect of lipopolysaccharide on cytokine secretion of peripheral blood mononuclear cells in the elderly population. Scand J Immunol 2011; 74: 603-8.
46. Abe R, Hirasawa H, Oda S, et al. Up-regulation of interleukin-10 mRNA expression in peripheral leukocytes predicts poor outcome and diminished human leukocyte antigen-DR expression on monocytes in septic patients. J Surg Res 2008; 147: 1-8. (Pubitemid 351626078)
47. Ereso AQ, Cureton EL, Cripps MW, et al. Lipoxin A4 attenuates microvascular fluid leak during inflammation. J Surg Res 2009; 156: 183-8.
48. Walker J, Dichter E, Lacorte G, et al. Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis. Shock 2011; 36: 410-6.
49. Bannenberg GL, Chiang N, Ariel A, et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345-55. (Pubitemid 40396017)
50. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8: 349-61. (Pubitemid 351595216)
51. Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007; 28: 176-83. (Pubitemid 46467520)
52. Das UN. Is sepsis a pro-resolution deficiency disorder? Med Hypotheses 2013; 80: 297-9.
53. Das UN. N-3 fatty acids, gamma-linolenic acid, and antioxidants in sepsis. Crit Care 2013; 17: 312.
54. Das UN. Molecular basis of health and disease. Springer, New York 2011.
55. Trostchansky A, Rubbo H. Nitrated fatty acids: mechanisms of formation, chemical characterization, and biological properties. Free Radic Biol Med 2008; 44: 1887-96.
56. Das UN. Relationship between gut and sepsis: role of ghrelin. World J Diabetes 2011; 2: 1-7.
57. Thompson JP, Serrano-Gomez A, McDonald J, Ladak N, Bowrey S, Lambert DG. The Nociceptin/Orphanin FQ system is modulated in patients admitted to ICU with sepsis and after cardiopulmonary bypass. PLoS ONE 2013; 8: e76682.
58. Brookes ZLS, Stedman EN, Brown NJ, et al. The Nociceptin/Orphanin FQ receptor antagonist UFP-101 reduces microvascular inflammation to lipopolysaccharide in vivo. PLoS ONE 2013; 8: e74943.
59. Qiang X, Yang WL, Wu R, et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med 2013; 19: 1489-95.
60. Piechota M, Barylski M, Hannam S, Mikhailidis DP, Rysz J, Banach M. Natriuretic peptides in septic patients. Curr Med Chem 2009; 16: 4020-31.
61. Piechota M, Barylski M, Hannam S, Piechota-Urbańska M, Banach M. Rationale of statin therapy in septic patients. Curr Vasc Pharmacol 2013; 11: 795-800.
62. Levy BD. Myocardial 15-Epi-lipoxin A4 generation provides a new mechanism for the immunomodulatory effects of statins and thiazolidinediones. Circulation 2006; 114: 873-5. (Pubitemid 44337129)
63. Birnbaum Y, Ye Y, Lin Y, et al. Augmentation of myocardial production of 15-Epi-Lipoxin-A4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929-35. (Pubitemid 44337136)